KLRD1 and Miyoshi myopathy: While PD-1 blockade has not been successful in MM, with clinical trials utilizing PD-1 inhibitors being suspended prematurely for increased mortality [28, 29], CD94/NKG2A-HLA-E axis represents an important immune checkpoint to study.